Kentucky Passes Bill to Allow Interchangeable Biosimilar Substitution

The Kentucky state Senate has passed a bill in a 36 to 1 vote that would permit interchangeable biosimilar substitution. The FDA has not yet approved an interchangeable biosimilar.

Under the bill, a pharmacist must inform the prescriber of the interchangeable biosimilar prescribed, along with the name and manufacturer, within five business days. The practitioner also reserves the right to forbid the substitution of a biologic.